Novo Nordisk (NVO), the world's largest insulin maker and a dominant force in obesity and diabetes treatments, has selected Amazon Web Services (AWS) as its preferred cloud and strategic artificial intelligence partner, aiming to speed up drug discovery and streamline operations across the pharmaceutical group. The partnership reflects a broader industry trend in which major drugmakers are turning to hyperscale cloud providers to compress the years-long, multibillion-dollar process of bringing new medicines to market. Novo Nordisk stock traded at $47.26, up 0.01%, after recovering from an early decline.

AWS Becomes Novo Nordisk's Strategic Cloud Partner

Under the agreement, Novo Nordisk will combine its disease expertise with AWS cloud and life sciences services. Research teams will use the partnership to process biological, clinical, imaging, and genomic data at a scale that traditional on-premise infrastructure struggles to match. The deal also supports broader development and deployment of internal digital systems.

The two companies have already collaborated on clinical documentation and employee productivity initiatives. Novo Nordisk reported that the work has reduced documentation time across several internal processes, and more than 25,000 employees have used productivity-enhancing tools developed through the partnership.

Novo Nordisk will leverage Amazon Bio Discovery and Amazon Bedrock for research and therapy design. The company also plans to deploy Bedrock AgentCore across selected operational workflows. AWS will provide scalable infrastructure for scientific workloads and complex research datasets.

London Innovation Hub Targets Faster Drug Development

Novo Nordisk and AWS have established a joint innovation hub at Novo's London facility, where engineers and scientists from both organizations will develop systems for medical research. The hub will focus on shortening the timeline from drug target identification to human dosing, a phase that traditionally can take several years and contribute heavily to development costs.

Teams at the hub will integrate genomic, imaging, and clinical data during early-stage development. Researchers will use this information to improve trial design and candidate assessment. Novo Nordisk intends to apply the approach across multiple chronic disease programs.

AWS will embed technical specialists within Novo Nordisk through its engineering organization. These teams will build systems spanning research, operations, data processing, and internal workflows, directly linking technology development to Novo Nordisk's scientific and operational priorities.

Expanded Amazon and Technology Partnerships

The agreement extends an existing relationship between Novo Nordisk and several Amazon businesses, including Amazon Pharmacy, Amazon Ads, and Amazon One Medical. The latest deal broadens that relationship into research infrastructure and internal technology operations.

Novo Nordisk has also expanded other technology partnerships across its global operations. The company has collaborated with OpenAI on broader adoption of advanced digital tools and has utilized Denmark's national supercomputer to support research workloads, notably including artificial intelligence applications for the company's R&D pipeline.

AWS has expanded its life sciences work with healthcare and biotechnology companies during 2026. Recent projects include drug discovery initiatives with Flagship Pioneering and surgical technology efforts with Johnson & Johnson. With this agreement, AWS adds another major pharmaceutical company to its growing healthcare technology portfolio, positioning itself alongside Microsoft and Google Cloud in the competitive race to serve the pharmaceutical sector's AI and data needs.